ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

Why Durvalumab is on this study

  • No treatment in the record names it; a reading of the whole record found it given.
  • Claude Opus 5.5 judged it tested: part of what the study tests (partner). Nov 16 (day only)“With tremelimumab and radiation before sarcoma surgery”
  • The role rule had no answer: no treatment entry names it.
  • So Durvalumab's page lists this study under “Testing it”.
5 links2 made here, not in the record7 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.govReplaced, or read an older versionMade here
Oct 19Oct 26Nov 2Nov 9Nov 16Nov 23TodayNCT03116529Neoadjuvant Durvalumab andTremelimumab Plus Radiationfor High Risk Soft-TissueSarcomaUniversity of Maryland, BaltimPhase 1/Phase 2 · terminatedRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 5 · ClinicalTrials.gov record · Version of 2026-11-05Nov 5 · Rule based · Reading set asideNov 16 · Rule based · Read againRead againCONDITIONSSarcomaThe registry's MeSH filing›As of now · Rule based · Main conditionMain conditionParkinson Disease 4, Autoso…The registry's MeSH filing›No judgment recorded. Shown as the registry files it.Diabetes Mellitus, Insulin-…The registry's MeSH filing›No judgment recorded. Shown as the registry files it.DRUGSDurvalumabMade here · Found by reading; no entr…›Nov 3 · Claude Opus 5.5 · BackgroundNov 16 · Claude Opus 5.5 · Tested · partnerTested · partnerTremelimumabMade here · Found by reading; no entr…›Nov 3 · Claude Opus 5.5 · TestedNov 16 · Claude Opus 5.5 · TestedTested

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

All judgments on this study

WhenLinkJudgeDecisionState
1 version of the record seen on ClinicalTrials.gov, Nov 5 · changes seen, not judgments
Nov 3Durvalumabmade hereClaude Opus 5.5BackgroundReplaced
Nov 3Tremelimumabmade hereClaude Opus 5.5TestedReplaced
Nov 5The record itselfRule based · nightly checkReading set asideCurrent
Nov 16The record itselfRule based · nightly checkRead againCurrent
Nov 16Durvalumabmade hereClaude Opus 5.5Tested · partnerCurrent
Nov 16Tremelimumabmade hereClaude Opus 5.5TestedCurrent
As of nowSarcomaRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

When a study changes after it was read

Every night, studies whose record changed are compared with the last reading. A change to sites or dates leaves the reading as it is; a reworded entry keeps it; a change to the treatments or conditions marks it to be read again.

Until it is read again, the page shows the last reading and says so.